BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Patients can now benefit from same-day procedure to diagnose and treat lung cancer

Imagine being diagnosed with lung cancer and having the tumor surgically removed on the same day, thereby increasing the opportunity for limited follow-up ...

February 22, 2022 | News

First Proton Therapy Treatment Delivered in Southeast Asia

The Varian ProBeam uses sophisticated imaging to see, adapt, and deliver treatment to the designated site, using a powerful particle accelerator called the...

February 09, 2022 | News

mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN

New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine ...

February 08, 2022 | News

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology

Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research based on discoveries published in leading scientif...

February 04, 2022 | News

Reaction Biology Announces Integrated Drug Discovery Solution

The Reaction Oncology Platform is based on a network of strategic partners, including oncology and biophysics by the US and Germany-based Reaction Biology,...

February 03, 2022 | News

BioMed X Institute and Merck KGaA, Extend Collaboration in Oncology

German independent research institute BioMed X announces today the extension of its collaboration with Merck KGaA, Darmstadt, Germany, in the res...

February 01, 2022 | News

Debiopharm and Aspen Partner to launch prostate cancer drug trelstar® in South Africa

In 2020, nearly 14,000 South African men were newly diagnosed with prostate cancer1 with an average of 5 men dying from the disease every day.2 I...

February 01, 2022 | News

Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia

Illumina, Inc. (NASDAQ: ILMN) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's hig...

January 25, 2022 | News

Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

Analysis of 1,000+ patients, with 12 months mean follow up, demonstrates clinical utility of Signatera for informing post-surgical treatment decisions &nb...

January 24, 2022 | News

Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan

Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing tra...

January 04, 2022 | News

First Approval in Japan for the KEYTRUDA Plus LENVIMA Combination

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare (M...

December 29, 2021 | News

Regor Therapeutics announced authorization from the USFDA to proceed with Regor's Phase 1 clinical development plans for RGT-419B.

On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration ...

December 28, 2021 | News

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developin...

December 20, 2021 | News

"We are thinking about new ways for the HCPs to engage with their patients that will be integrated with existing healthcare IT systems" : Dr Richard Banbury

What could be the impact of new COVID-19 variants on global oncology services? This pandemic has disrupted the spectrum of oncology care and poses...

December 17, 2021 | Opinion

Stay Connected